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Summary
Background—To combat Neisseria meningitidis serogroup A epidemics in the meningitis belt of 
sub-Saharan Africa, a meningococcal serogroup A conjugate vaccine (MACV) has been 
progressively rolled out since 2010. We report the first meningitis epidemic in Niger since the 
nationwide introduction of MACV.
Methods—We compiled and analysed nationwide case-based meningitis surveillance data in 
Niger. Cases were confirmed by culture or direct real-time PCR, or both, of cerebrospinal fluid 
specimens, and whole-genome sequencing was used to characterise isolates. Information on 
vaccination campaigns was collected by the Niger Ministry of Health and WHO.
Findings—From Jan 1 to June 30, 2015, 9367 suspected meningitis cases and 549 deaths were 
reported in Niger. Among 4301 cerebrospinal fluid specimens tested, 1603 (37·3%) were positive 
for a bacterial pathogen, including 1147 (71·5%) that were positive for N meningitidis serogroup 
C (NmC). Whole-genome sequencing of 77 NmC isolates revealed the strain to be ST-10217. 
Although vaccination campaigns were limited in scope because of a global vaccine shortage, 1·4 
million people were vaccinated from March to June, 2015.
Interpretation—This epidemic represents the largest global NmC outbreak so far and shows the 
continued threat of N meningitidis in sub-Saharan Africa. The risk of further regional expansion of 
this novel clone highlights the need for continued strengthening of case-based surveillance. The 
availability of an affordable, multivalent conjugate vaccine may be important in future epidemic 
response.
Introduction
In Niger and elsewhere in the meningitis belt of sub- Saharan Africa, endemic 
meningococcal disease and annual outbreaks have been punctuated every 5–12 years by 
large-scale epidemics, which were historically caused by Neisseria meningitidis serogroup A 
(NmA).1 In 2010–11, a novel meningococcal serogroup A conjugate vaccine (MACV), 
MenAfriVac, was introduced in Niger through preventive mass vaccination campaigns, with 
the goal of eliminating NmA epidemics. In the 5 years after the introduction of this vaccine, 
annual cases of suspected meningitis reached the lowest reported levels in Niger, and no 
NmA cases were confirmed (WHO, unpublished). With the progressive roll-out of MACV in 
16 countries in sub-Saharan Africa (as of December, 2015), no NmA epidemics have been 
reported in vaccinated areas.2
Despite the early success of MACV in the prevention of NmA disease and epidemics, other 
meningococcal serogroups have caused meningitis epidemics in sub- Saharan Africa. 
Several epidemics due to N meningitidis serogroup W (NmW) have occurred since the first 
major epidemic in Africa was reported in 2002 in Burkina Faso, with NmW as the leading 
meningococcal cause of meningitis in sub-Saharan Africa in the years following MACV 
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introduction.2–7 Additionally, smaller epidemics caused by N meningitidis serogroup X 
(NmX) have been reported in Burkina Faso, Niger, and Togo.8,9 Although N meningitidis 
serogroup C (NmC) cases have occasionally been reported in Niger and elsewhere in the 
meningitis belt, NmC epidemics are rare.1,10
Before 2013, the last known predominantly NmC outbreak in Africa was reported in 1979 in 
Burkina Faso.11 In 2013–14, outbreaks caused by a novel NmC clone were reported in two 
neighbouring states of northern Nigeria,12 and were relatively small and focal compared 
with the large-scale NmA epidemics. In March, 2015, NmC cases were first detected in the 
Dogon-Doutchi district of Niger along the Nigerian border, with subsequent spread to other 
regions in Niger. In this report, we describe the emergence of NmC in Niger that resulted in 
the first large-scale NmC epidemic in sub-Saharan Africa.
Research in context
Evidence before this study
We searched the PubMed MeSH database for English-language articles published from 
database inception to April 24, 2016, using the terms “Neisseria meningitidis”, “Neisseria 
meningitidis, serogroup C”, “meningitis, meningococcal”, “epidemic”, “meningococcal 
vaccines”, “Africa south of the Sahara”, and “Niger”. Until the introduction of a 
meningococcal serogroup A conjugate vaccine (MACV), MenAfriVac, in the meningitis 
belt of sub-Saharan Africa starting in 2010, large meningitis epidemics have primarily 
been caused by N meningitidis serogroup A (NmA). Sporadic cases and localised 
epidemics due to N meningitidis serogroup C (NmC) have rarely been reported in the 
meningitis belt of sub-Saharan Africa, and the sequential NmC outbreaks in Nigeria in 
2013–14 were relatively small and focal. No large-scale NmC epidemics have previously 
been reported.
Added value of this study
9367 suspected meningitis cases, including 1147 confirmed NmC cases, were reported in 
Niger from Jan 1 to June 30, 2015. We describe the epidemiological and microbiological 
features of the first large-scale NmC epidemic in sub-Saharan Africa and the largest 
global NmC outbreak so far. Our report of this NmC epidemic shows the continued threat 
of meningococcal epidemics despite the successful introduction of MACV in sub-
Saharan Africa.
Implications of all the available evidence
Case-based surveillance and laboratory capacity need to be strengthened to monitor the 
evolving epidemiology of meningococcal meningitis in the meningitis belt in the post-
MACV era and to respond rapidly to disease outbreaks. Additionally, this epidemic 
highlights the need for an adequate global supply of affordable, multivalent 
meningococcal vaccines to respond to non-serogroup A meningococcal meningitis 
epidemics in sub-Saharan Africa.
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Methods
Data collection
In this study, we compiled and analysed nationwide case-based surveillance data of all 
reported meningitis cases in Niger from Jan 1 to June 30, 2015, to describe the 
epidemiological and microbiological features of the epidemic. We collected epidemiological 
data of reported meningitis cases through complementary aggregate, case-based, and 
enhanced meningitis surveillance systems. In the aggregate system, population-based 
meningitis surveillance is conducted in all 44 functional health districts, with weekly 
transmission of district-level suspected meningitis cases and death counts. Case-based 
meningitis surveillance, in which detailed epidemiological and laboratory data are collected 
for each suspected meningitis case through a standardised case investigation form, is 
conducted in eight of 44 districts representing 37% of Niger’s population as of December, 
2014 (Dogon-Doutchi, Filingué, Madaoua, Madarounfa, Maradi, Niamey I, Say, and Tera). 
In the nationwide enhanced meningitis surveillance, case-level demographic data are 
collected and transmitted weekly through a line list, with the same standardised case 
investigation form used for case-based surveillance, during meningitis epidemics. In each of 
these surveillance systems, epidemiological data are transmitted from the health facility to 
the district surveillance office, followed by the regional surveillance office, and finally to the 
national level.
Procedures and statistical analyses
Laboratory analyses on cerebrospinal fluid specimens from patients with reported meningitis 
were completed at the Centre de Recherche Médicale et Sanitaire (CERMES), the national 
meningitis reference laboratory in Niger. We used culture or direct real-time PCR testing, or 
both, for detection of N meningitidis, Haemophilus influenzae, and Streptococcus 
pneumoniae.13 Serogroup was deter mined on isolates by slide agglutination and on 
cerebrospinal fluid specimens that were PCR positive for N meningitidis by serogroup-
specific direct real-time PCR. Culture and slide agglutination were also conducted at the 
Hôpital National de Niamey and a mobile laboratory (LaboMobil, Agence de Médecine 
Préventive) deployed to a temporary treatment centre in Niamey. External quality assurance 
of culture and PCR results obtained at CERMES was done collectively by the WHO 
Collaborating Centres for Meningitis at the US Centers for Disease Control and Prevention, 
Institut Pasteur, and Norwegian Institute of Public Health, on 111 specimens.
Cases were defined according to WHO guidelines.14 A suspected meningitis case was 
defined by the presence of sudden onset of fever with headache and one of the following 
signs: stiff neck, altered consciousness, or other meningeal signs. A probable case is defined 
as a suspected case with Gram-negative diplococci, Gram-positive diplococci, or Gram-
negative bacilli identified by Gram stain. A confirmed case was defined as a suspected or 
probable case for which N meningitidis, H influenzae, or S pneumoniae was isolated in 
culture or the DNA of these pathogens was detected by direct real-time PCR. We calculated 
cumulative incidence as the number of suspected meningitis cases reported per 100 000 
people, using age-specific and district-specific population data projected for 2015 from the 
2012 national census.15 The WHO alert threshold is defined as a weekly attack rate of three 
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to nine suspected cases per 100 000 people and the epidemic threshold as ten or more 
suspected cases per 100 000 people.16 We calculated the case fatality rate as the proportion 
of deaths among reported cases. Details on the reactive vaccination campaigns were 
obtained from the Niger Ministry of Health and WHO.17
We created a comprehensive, national case-based surveillance database of all suspected, 
probable, and confirmed meningitis cases reported during the epidemic period from Jan 1 to 
June 30, 2015, by harmonising case-level data collected from the enhanced and case-based 
surveillance databases and the databases from the three laboratories. We merged 
epidemiological and laboratory data using name, age, village, health facility, and onset date, 
with manual matching, verification, and de-duplication of records. We excluded cases from 
the database if no epidemiological data were available. Cases were subsequently assigned a 
unique identifier and the database was anonymised. The number of meningitis cases reported 
by region was compared with that reported in the aggregate surveillance system to assess 
sensitivity of the case-based surveillance system.
Isolates were characterised at the three WHO Collaborating Centres using whole-genome 
sequencing.18 Genome sequencing data were generated with both the PacBio RSII 
instrument (Pacific Biosciences, Menlo Park, CA, USA) and the Illumina HiSeq 2500 
(Illumina, San Diego, CA, USA). Multilocus sequence typing alleles were identified on the 
basis of a BLAST search of the assembled genomes against the PubMLST allele list.19 Porin 
A (PorA), porin B (PorB), and ferric enterobactin transport (FetA) were classified according 
to their respective variable regions.
Descriptive analyses were done with SAS version 9.3, Microsoft Excel, and ArcGIS.
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the 
data in the study and had final responsibility for the decision to submit for publication.
Results
From Jan 1 to June 30, 2015 (ie, epidemiological weeks 1–26), 9367 meningitis cases—
1604 (17·1%) confirmed cases, 64 (0·7%) probable cases, and 7699 (82·2%) suspected cases
—and 549 (5·9%) deaths were reported in the comprehensive case-based surveillance 
database. Cumulative national attack rate was 50·6 cases per 100 000 people. By 
comparison, fewer suspected meningitis cases (8661) but more deaths (589 [6·8%]) were 
reported during the same time period in the aggregate surveillance system. Most cases were 
from the regions of Niamey (6210 [71·7%], cumulative attack rate 566·5 cases per 100 000 
people), Dosso (1228 [14·2%], 41·4 cases per 100 000 people), and Tillaberi (1201 [13·9%], 
57·1 cases per 100 000 people).
The epidemic started in the Dosso region, when the first sub-district health area in the 
Dogon-Doutchi district crossed the epidemic threshold in week 7. Sub-district epidemics 
continued in Dogon-Doutchi through week 12, when the entire district crossed the threshold. 
Sidikou et al. Page 6
Lancet Infect Dis. Author manuscript; available in PMC 2017 December 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
The first district in Niamey region, Niamey II, crossed the epidemic threshold in week 13, 
and by week 17, all five districts in Niamey had crossed the epidemic threshold. The 
epidemic peaked in week 19; by week 20, 12 of the 44 districts in Niger had crossed the 
weekly epidemic threshold and six had crossed the weekly alert threshold (figure 1). Among 
the 9367 total cases, 8453 (90·2%) were reported from epidemic districts, 440 (4·7%) from 
alert districts, and 474 (5·1%) from districts that remained below the alert threshold. The 
epidemiological curve was compared with previous epidemics in Niger from 2003 to 2015 
(figure 2).
Of 5059 (54·0%) individuals with suspected meningitis who were reported to have had 
lumbar puncture for cerebrospinal fluid collection, 4301 (85·0%) had their cerebrospinal 
fluid specimens received by a laboratory performing confirmatory testing and had a case 
report form available. 1603 (37·3%) specimens tested positive: 1147 (71·5%) were positive 
for NmC, 236 (14·7%) NmW, 90 (5·6%) undetermined N meningitidis, one (0·06%) NmX, 
121 (7·5%) S pneumoniae, and eight (0·5%) H influenzae serotype b. Of the 4136 (96·2%) 
specimens analysed at CERMES, 4132 (99·9%) were analysed by PCR and 353 (8·5%) by 
culture. External quality assurance testing on 111 specimens showed 100% concordance 
with results obtained at CERMES.
At the beginning of the epidemic (weeks 11–14), the proportion of NmC and NmW cases 
among N meningitidis cases with known serogroup was roughly equal. From week 15 
onwards, the proportion of weekly NmC cases predominated (82–90%; figure 3). This 
predominance of NmC cases was only observed in the 18 districts that exceeded the alert or 
epidemic threshold, whereas in districts that remained below the thresholds, the distribution 
of NmC and NmW cases remained roughly equal (53·6% vs 46·4%). The age distribution 
differed in individuals with confirmed NmC cases and in those with confirmed NmW and S 
pneumoniae cases (table).
549 deaths were reported, although 7143 (76·3%) of 9367 patients had unknown outcome. In 
all reported cases, the case fatality rate was 5·9%. However, when the analysis was restricted 
to the 2224 cases with known outcome, the case fatality rate was much higher (24·7%). The 
case fatality rates were 8·5% in the 1604 laboratory-confirmed cases and 22·7% in the 603 
laboratory-confirmed cases with known outcomes (table).
Reactive vaccination campaigns were introduced at the sub-district level of 13 districts from 
March to June, 2015 (weeks 13–26). 1·4 million doses of meningococcal vaccines were 
made available from the national stockpile, from a neighbouring country’s stockpile, and 
through five separate requests to the global emergency stockpile managed by the 
International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control. 12 
districts rolled out trivalent (serogroups A, C, and W) or tetravalent (serogroups A, C, W, 
and Y) polysaccharide meningococcal vaccines in children aged 2–15 years, achieving an 
overall administrative coverage in targeted subgroups of 62·4% (619 435 of 992 085). The 
13th district, Ouallam, was the first to use the quadrivalent conjugate meningococcal vaccine 
MenACWY-D (serogroups A, C, Y, and W) for outbreak response in Africa, and the 
campaign achieved a 96·1% (188 129 of 195 772) coverage in children aged 2–19 years. 
However, a global shortage in polysaccharide meningococcal vaccines limited the scope and, 
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in some districts, the timeliness of the reactive campaigns. Vaccination campaigns were 
restricted to children aged 2–15 years or 2–19 years instead of the entire at-risk population 
(ie, those aged 2–29 years), and sub-district health areas were targeted instead of the entire 
district. Children younger than 2 years were not targeted for vaccination because 
polysaccharide vaccines are not immunogenic in this age group and the need for a two-dose 
conjugate MenACWY-D series in children aged 9–23 months was not feasible. Roughly 
one-third of the total vaccine doses became available in June, 2015, after the epidemic had 
largely subsided.
We used whole-genome sequencing to characterise 98 isolates. All 77 NmC isolates were 
PorA P1·21-15,16, PorB 3-463, FetA 1-7, and ST-10127, belonging to an unassigned clonal 
complex.18 ST-10127 is distinct and has only been previously identified from outbreaks in 
Nigeria in 2013–14.12 All 21 NmW isolates were ST-11 that belonged to clonal complex 11, 
with identical PorA (P1·5,2) but different PorB and FetA sequences. 14 NmW isolates had 
PorB 2-2, six had PorB 2-277, and one had PorB 2-60. 15 NmW isolates had FetA 1-1, and 
six had FetA type 1-84. All NmW isolates were closely related to other recent isolates from 
sub-Saharan Africa.18 Detailed description of NadA, NhbA, and FHbp sequences, as well as 
phylogenetic analysis of strains, is presented elsewhere.18
Discussion
The occurrence of a large-scale NmC epidemic in sub- Saharan Africa in the years following 
successful mass vaccination with MACV shows the continued risk of meningitis epidemics 
in the region. As the largest known NmC epidemic so far on a global scale and the first 
major NmC epidemic in Africa, the 2015 epidemic in Niger is further evidence of the 
evolving epidemiology of bacterial meningitis in the meningitis belt. Although it is too early 
to fully describe the epidemic potential of NmC in sub- Saharan Africa, evidence shows 
regional spread, with NmC cases reported in 2016 in Burkina Faso, Mali, Côte d’Ivoire, and 
Ghana, in addition to further localised outbreaks in Niger and Nigeria.20
Compared with epidemics caused by serogroups A, W, and X in the past 15 years in Niger, 
this NmC epidemic is most notable for the rapid acceleration to its peak, which occurred late 
in the epidemic season, following several years of historically low case counts. Although the 
NmC epidemic did not match the magnitude of the largest NmA epidemics in Niger (eg, the 
2009 epidemic with nearly 14 000 cases reported),21 greater numbers of cases were reported 
during the NmC epidemic (9367 total cases) than in the 2010 mixed NmA–NmW epidemic 
(nearly 3000 total cases4) and the 2006 mixed NmA–NmX epidemic (more than 4000 total 
cases).8 The age distribution of NmC cases, with the highest proportions observed in 
adolescents and young adults, is similar to that reported in previous NmA epidemics,22 
whereas the predominance of NmW cases in children younger than 5 years has been 
reported in other NmW epidemics.4,6 The overall case fatality rate of 5·9% in this NmC 
epidemic is consistent with that reported in several NmA, NmW, and NmX epidemics in 
Niger (roughly 4–8%),4,8,21–23 although the incompleteness of case outcome in the 
surveillance data limits the interpretation of these results.
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Analyses of strains from countries in the meningitis belt from the past 50 years show that 
most epidemics have been caused by the introduction of successive clonal waves from 
hyper-invasive lineages in a naive population.24 Similar to previous reports,25 the novel 
NmC clone causing this epidemic emerged following clonal waves of serogroup A. Thus, 
immunity against NmC in this population is expected to be low or nonexistent because of the 
infrequency of sporadic cases or epidemics, low NmC carriage,26 and the lack of recent 
vaccinations in the region with serogroup C-containing vaccines. Since the ST-10217 strain 
causing this epidemic is highly distinct from encapsulated meningococcal strains of any 
serogroup in global strain collections, there is no evidence for vaccine-induced capsular 
switching as a factor in this epidemic.18 Although it is too early to determine whether 
serogroup replacement, in which non-vaccine serogroups expand in the ecological niche left 
after MACV-induced reductions in serogroup A meningococcal carriage, is a factor in the 
emergence of NmC epidemics in Niger and Nigeria, the overall incidence of suspected 
meningitis in the meningitis belt, excluding the NmC epidemic in Niger, has decreased since 
the introduction of MACV.2,27,28 Thus, the rapid spread of this epidemic is likely to result 
from the introduction of this novel hypervirulent clone in an immunologically naive 
population. However, molecular surveillance and additional carriage studies are needed for 
continued monitoring of the changing epidemiology of meningococcal disease and 
epidemics and of the long-term effects of MACV in the meningitis belt.
The prevention of NmC and other non-serogroup A meningitis epidemics in Africa remains 
an elusive goal because affordable multivalent conjugate vaccines are not available. 
Compared with conjugate vaccines, polysaccharide vaccines have a shorter estimated 
duration of protection and do not reduce acquisition of naso-pharyngeal carriage of N 
meningitidis, making them ineffective for the prevention of meningococcal outbreaks. 29 
The current quadrivalent meningococcal conjugate (MenACWY) vaccines, marketed at more 
than US$100 per dose in the USA,30 are unaffordable for widespread use in Africa, even 
with a substantially reduced price such as that negotiated for the campaign in Ouallam of 
$25 per dose. Preventive vaccination is therefore prohibitively expensive. An affordable 
pentavalent conjugate meningococcal vaccine (MenACWXY), which is being developed for 
use in Africa, will not be licensed until 2019 at the earliest.31
The NmC epidemic in Niger shows the importance of case-based surveillance as a 
complement to enhanced and aggregate meningitis surveillance during epidemics. The 
massive scale-up effort of epidemic response activities in a very short time period, along 
with the ongoing shortage of polysaccharide meningococcal vaccines, highlights the need 
for rapid detection, confirmation, and characterisation of the epidemic at the sub-district 
level to optimise public health interventions, including reactive vaccination campaigns, that 
target the population at highest risk. Additionally, as the epidemic evolved from an equally 
mixed NmC–NmW epidemic to a predominantly NmC epidemic, strong capacity for culture 
and PCR testing at referral laboratories with linkage to epidemiological data is crucial for 
real-time decision making of vaccination campaigns and appropriate stewardship of limited 
vaccine stocks.
Although the continued absence of NmA in the 5 years since Niger successfully introduced 
MACV highlights the remarkable success of this vaccine, the NmC epidemic in Niger shows 
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the continued threat of meningococcal epidemics in the meningitis belt. The risk of further 
regional expansion of NmC underscores the need for continued strengthening of case-based 
surveillance with rapid laboratory confirmation and molecular characterisation of strains. 
Additionally, the availability of an affordable multivalent conjugate vaccine in the global 
emergency stockpile to respond to non-serogroup A meningococcal epidemics may be 
important in future epidemic response.
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Figure 1. Districts that surpassed epidemic or alert thresholds in Niger, Jan 1 to June 30, 2015
*Includes five districts: Niamey I, Niamey II, Niamey III, Niamey IV, and Niamey V.
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Figure 2. Number of suspected meningitis cases by week in Niger (A) between Jan 1, 2003, and 
June 30, 2015, and (B) during selected epidemic years
In the epidemics of 2003, 2004, 2008, and 2009, Neisseria meningitidis serogroup A was the 
predominant serogroup. In the 2006 epidemic, N meningitidis serogroup X was the 
predominant serogroup. In the epidemic of 2015, N meningitidis serogroup C was the 
predominant serogroup. MACV=serogroup A conjugate meningococcal vaccine.
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Figure 3. Laboratory-confirmed cases by epidemiological week and pathogen, Jan 1 to June 30, 
2015
NmC=Neisseria meningitidis serogroup C. NmW=N meningitidis serogroup W.
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